SCHEMBL876543

SCHEMBL876543

OCc1ccc(Oc2cccc(C(F)(F)F)c2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.48
TLR7 Q9NYK1 1/20 0.48
HTR2A P28223 3/20 0.45
SLC6A4 P31645 3/20 0.45
KCNH2 Q12809 3/20 0.45
LTA4H P09960 1/20 0.45
MAPK14 Q16539 1/20 0.43
MAOB P27338 1/20 0.43
AOC3 Q16853 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PIM1 P11309 1/20 0.43
PDGFRA P16234 1/20 0.43
S1PR1 P21453 1/20 0.43
S1PR5 Q9H228 1/20 0.43
KIF11 P52732 1/20 0.42
EPAS1 Q99814 1/20 0.42
CETP P11597 1/20 0.41
PPARG P37231 3/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12806603 0.86 CETP (0.48) TLR8TLR7HTR2ASLC6A4KCNH2
SCHEMBL876364 0.85 LTA4H (0.47) TLR8TLR7LTA4HMAPK14MAOB
SCHEMBL27717360 0.84 THRB (0.52) TLR8TLR7MAPK14SMN1; SMN2PIM1
SCHEMBL3300560 0.83 TLR8 (0.44) TLR8TLR7HTR2ASLC6A4KCNH2
SCHEMBL883737 0.83 PPARG (0.50) LTA4HMAPK14MAOBAOC3SMN1; SMN2
SCHEMBL16199417 0.83 LTA4H (0.45) TLR8TLR7LTA4HMAPK14MAOB
SCHEMBL3299567 0.81 TLR8 (0.42) TLR8TLR7HTR2ASLC6A4KCNH2
SCHEMBL9160188 0.81 TLR8 (0.51) TLR8TLR7LTA4HKIF11PPARG
SCHEMBL3120483 0.81 S1PR1 (0.45) TLR8TLR7HTR2ASLC6A4KCNH2
SCHEMBL3304680 0.81 S1PR1 (0.42) TLR8TLR7HTR2ASLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
EP-2619203-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES Glaxo Group Limited (GB) 2013-07-31 EP disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 TLR8 1322/4885TLR7 1835/4885HTR2A 1581/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 TLR8 1322/4885TLR7 1835/4885HTR2A 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.